计算溶液所需的质量、体积或浓度。
Rontalizumab (anti-IFNA1) (Ab175647) - ELISA
Immobilized Human IFNa1, Fc tag at 2.0 μg/mL can bind Rontalizumab (anti-IFNA1) (Ab175647) with the EC₅₀ of 54.44 ng/mL.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| Ab175647-1mg |
1mg |
现货 ![]() |
| |
| Ab175647-100μg |
100μg |
现货 ![]() |
| |
| Ab175647-5mg |
5mg |
现货 ![]() |
| |
| Ab175647-10mg |
10mg |
期货 ![]() |
|
| 产品名称 | Rontalizumab (anti-IFNA1), 干扰素α抑制剂 |
|---|---|
| 别名 | 隆利组单抗 | 隆达珠单抗(抗 IFNA1) |
| 英文别名 | IFL antibody | IFN alpha antibody | IFN alpha 1/13 antibody | IFN alpha 1b antibody | IFN alphaD antibody | IFN antibody | IFN-alpha-1/13 antibody | IFNA@ antibody | IFNA1 antibody | IFNA1_HUMAN antibody | Interferon alpha 1 antibody | IFNA13 antibody | I |
| 规格或纯度 | 无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA |
| 宿主种属 | 人(Human) |
| 特异性 | IFNA1; IFNA13 |
| 种属反应性 | 人(Human) |
| 偶联 | Unconjugated |
| 作用类型 | 抑制剂 |
| 作用机制 | 干扰素α抑制剂 |
| 克隆类型 | 重组抗体 |
|---|---|
| Format | Whole IgG |
| 亚型 | Human IgG1 |
| 轻链亚型 | kappa |
| SDS-PAGE | 27.0 kDa (Light Chain) & 51.1 kDa (Heavy Chain), under reducing conditions; 196.4 kDa, under non-reducing conditions. |
| 纯化方法 | Protein A purified |
| 纯度 | >95% (SDS-PAGE&SEC) |
| 物理外观 | Liquid |
| 储存缓冲液 | Supplied as a 0.22μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH5.0. |
| 防腐剂 | No |
| 浓度 | 见COA |
| 储存温度 | -80℃储存,避免反复冻融 |
| 运输条件 | 超低温冰袋运输 |
| 稳定性与储存 | 在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。 |
| CAS编号和信息 | 948570-30-7 |
| 分子类型 | 抗体 |
Rontalizumab (anti-IFNA1) (Ab175647) - ELISA
Immobilized Human IFNa1, Fc tag at 2.0 μg/mL can bind Rontalizumab (anti-IFNA1) (Ab175647) with the EC₅₀ of 54.44 ng/mL.
Rontalizumab (anti-IFNA1) (Ab175647) - SEC
The purity of Rontalizumab (anti-IFNA1) (Ab175647) is more than 95% verified by HPLC.
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
¥719.90
| 1. Chuntharapai A, Lai J, Huang X, Gibbs V, Kim KJ, Presta LG, Stewart TA. (2001) Characterization and humanization of a monoclonal antibody that neutralizes human leukocyte interferon: a candidate therapeutic for IDDM and SLE.. Cytokine, 15 (5): (250-60). [PMID:11594789] |
| 2. Kalunian KC. (2016) Interferon-targeted therapy in systemic lupus erythematosus: Is this an alternative to targeting B and T cells?. Lupus, 25 (10): (1097-101). [PMID:27497254] |
| 3. Kalunian KC, Merrill JT, Maciuca R, McBride JM, Townsend MJ, Wei X, Davis Jr JC, Kennedy WP. (2016) A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE).. Ann Rheum Dis, 75 (1): (196-202). [PMID:26038091] |
| 4. Maurer B, Bosanac I, Shia S, Kwong M, Corpuz R, Vandlen R, Schmidt K, Eigenbrot C. (2015) Structural basis of the broadly neutralizing anti-interferon-α antibody rontalizumab.. Protein Sci, 24 (9): (1440-50). [PMID:26099203] |